News|Articles|December 19, 2013

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-01-08-2014
  • Volume 10
  • Issue 1

Cambrex Completes FDA Inspection

FDA completes an inspection of Cambrex's API manufacturing facility in Charles City, Iowa.

Cambrex reported that FDA completed an inspection of Cambrex’s API manufacturing facility in Charles City, Iowa. The inspection found the site to be compliant with the principles and guidelines of GMP and no Form 483 observations were issued. FDA authorities inspected the facility from July 31 to August 2, 2013.

This follows successful inspections at Charles City made previously by FDA in March 2010 and February 2012, neither of which resulted in any issued 483 observations, the Korean FDA in January 2012 and the Medicines and Healthcare Products Regulatory Agency of the UK October 2011, after which a GMP certificate for a drug product intermediate was issued.

Source: Cambrex


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.